Navigation Links
Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease
Date:10/8/2007

SAN DIEGO, Oct. 8 /PRNewswire/ -- Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases announced today that it has completed the patient enrollment of its Phase 3 study in fistulizing Crohn's disease. This pivotal, double-blind, placebo controlled study, FHAST1 (Fistula Healing with AST-120), has been designed to determine the efficacy and safety of oral AST-120 in 240 patients with Crohn's disease suffering from perianal fistulas. Initial data from the trial will be available in the first quarter of 2008.

"We are very pleased to have completed the enrollment in our FHAST1 pivotal trial evaluating AST-120 in a timely manner," stated Laurent Fischer, M.D., President and CEO of Ocera Therapeutics. "We would like to thank our investigators and patients in North America, Europe and Israel for their participation in the study."

Data from a double blind, placebo controlled Japanese study of AST-120 in fistulizing Crohn's disease sponsored by Kureha and presented at the Digestive Disease Week in May 2006 demonstrated that AST-120 significantly reduces draining fistulas compared to placebo.

"Up to one third of patients with Crohn's disease suffer from draining perianal fistulas, a chronic and debilitating condition that significantly affects their quality of life," said Professor Stephen Hanauer, M.D., Director of the Section of Gastroenterology and Nutrition at the University of Chicago and the Principal Investigator in the study. "Despite effective treatments, there is an unmet need for new and well-tolerated oral agents for patients with mild to moderate Crohn's disease who suffer from fistulas."

"We were pleased to participate in this Phase 3 trial evaluating the efficacy and safety of AST-120, a new oral treatment option, in fistulizing Crohn's disease," added Professor Simon Travis, M.D., Clinical Directo
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
5. Celsion Completes Enrollment in Phase I Liver Cancer Study
6. LANI completes Phase I in Japan and to commence Phase I in UK
7. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... de mayo de 2013  Volcano Corporation (NASDAQ: ... fabricante de herramientas de precisión para terapia guiadas ... la enfermedad vascular periférica y coronaria, anunció hoy ... enosine V asodilator I ndependent ... sesión de ensayo clínico hot line late breaking ...
(Date:5/23/2013)... OAKS, Calif. , May 23, 2013 Amgen ... Bank 38 th Annual  Healthcare Conference on Thursday, May ... Boston , beginning at 9:20 a.m. Eastern Daylight Time. ... Relations at Amgen, will present at the conference. Live audio ... on Amgen,s website, www.amgen.com , under Investors. A replay ...
(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering.  In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering.   A ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... WILMINGTON, Del. , April 30 ... and Drug Administration (FDA) has approved VIMOVO™ ... of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ... gastric ulcers in patients at risk of developing NSAID-associated ...
... The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine ... as its July 2010 "Stock to Study" and Gilead ... for investors, informational and educational use. , ... "The committee chose Teva Pharmaceutical Industries because of the tremendous ...
Cached Medicine Technology:FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 2FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 3FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 4FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 5FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 6FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 7FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 8FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 9BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 2BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 3
(Date:5/24/2013)... 25, 2013 Part guidebook, part memoir, ... a tried and true approach to meditation for the ... Mastering the 11th Step, the book outlines a comprehensive ... of the 11th step in any 12-step recovery programs ... drug dependence an ever-growing global health problem affecting the ...
(Date:5/24/2013)... 2013 Range Kleen Mfg. strives to “TCOTC.” ... Customer, from the President's desk to the Shipping Dock.” We ... integrity, and having passion while creating excellence and quality being ... company to do the right thing and what better way ... affected by devastation. , Throughout the year Range Kleen donates ...
(Date:5/24/2013)... New York, New York (PRWEB) May 24, 2013 ... from the 2010 DePuy hip recall continue to move ... reports. According to documents filed in California’s San ... had been seeking an expedited trial of her DePuy ... (Tilman v. DePuy Orthopaedics, Inc., et al., No. ...
(Date:5/24/2013)... 2013 ResortQuest Real Estate® is proud ... Feher team at the firm’s Bethany Beach location. , ... her home in 1975. Her real estate career began ... aspects of the real estate business - receptionist, cleaning ... years, a licensed sales associate. , “I am ...
(Date:5/24/2013)... research suggests a link between sleep duration and ... additional hour someone with insomnia sleeps is associated ... of moderate or high risk of suicide, according ... "We were surprised by the strength of ... study author, Linden Oliver, clinical research coordinator for ...
Breaking Medicine News(10 mins):Health News:Guidebook for Recovery Published by Meditation Master Peter Amato 2Health News:Guidebook for Recovery Published by Meditation Master Peter Amato 3Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 3Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 4Health News:Tammy Mushrush Joins ResortQuest Real Estate® and the Dayna Feher Team 2Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2
... , , , ALISO ... a premier technology and services resource for pathologists, oncologists and the pharmaceutical ... at the Canaccord Adams 29th Annual Global Growth Conference at 8:00 am ... the InterContinental Boston Hotel, August 11-13, 2009. , , ...
... ... a change in state health policies, will soon be without health says MedicareSupplementPlans.com . ... Los Angeles, CA (Vocus) ... the uninsured over the next four years if there are no changes in state health ...
... ... Managing Mood, Food and Weight ." The book is designed to provide a roadmap for ... mental and physical health. , ... (PRWEB) August 5, 2009 -- Author Sarah Freeman has overcome many challenges when ...
... ... Employers , ... August 5, 2009 -- United Benefit Advisors (UBA), in partnership with the National Association of ... Thursday, Aug. 13, regarding what,s happening now in the national health care reform debate., , ...
... ... PC Magazine and others , ... Destin, FL (PRWEB) August 4, 2009 -- In 1999 Christina Timmons parlayed a background in ... O.I.S. Media, launched MDJobSite.com, http://www.mdjobsite.com , a physician job search website that ...
... , , SEATTLE, Aug. 5 ... Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.,s (CTI) (Nasdaq ... discuss the Company,s 2009 second quarter financial results. , , ... Thursday, August 6, 8:30 a.m. Eastern/2:30 p.m. ...
Cached Medicine News:Health News:Clarient to Present at Canaccord Adams 29th Annual Global Growth Conference on Wednesday, August 12th 2Health News:Number of Californians with No Health Insurance is Rising says MedicareSupplementPlans.com 2Health News:New Book Helps Those with Bipolar Disorder Manage Diets - and Lives 2Health News:UBA offers Free Webinar: NAHU Executive VP and CEO to Discuss Health Reform Bills 2Health News:UBA offers Free Webinar: NAHU Executive VP and CEO to Discuss Health Reform Bills 3Health News:Ten Years Later: O.I.S. Media Leads Physician Job Board Industry with Innovative Technology 2
... Diagnostics Histoplasma DxSelect is intended for qualitatively ... in human serum. The test is indicated ... disease, as an aid in the presumptive ... is not intended for self-testing, and this ...
... Indirect immunofluorescent antibody (IFA) ... and semi-quantitation of human ... Epstein-Barr viral capsid antigen ... ten 12-well slides, FITC ...
... portable, battery-powered, micro-controlled, noninvasive bone growth stimulator ... primary lumbar spinal fusion surgery for one ... been shown in pre-clinical studies to help ... Clinical studies have also shown that individuals ...
... Medical Solutions introduces its new multifunctional ... with intuitive patient data management is ... and urological table. Lithoskop is an ... that covers all applications like lithotripsy, ...
Medicine Products: